MedTrace Logo

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

NCT05736965 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-03-15

No results posted yet for this study

Summary

This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.

Conditions

  • AML, Adult

Interventions

DRUG

Selinexor

Selinexor 60mg, PO d3,10,17

DRUG

Azacitidine

Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16

DRUG

Venetoclax

Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14

Sponsors & Collaborators

  • Shanghai Tong Ren Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2025-03-30
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05736965 on ClinicalTrials.gov